Literature DB >> 15197702

Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease.

William C Nichols1, Sean K Uniacke, Nathan Pankratz, Terry Reed, David K Simon, Cheryl Halter, Alice Rudolph, Clifford W Shults, P Michael Conneally, Tatiana Foroud.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder in humans with wide variability in the age of disease onset. Although the disease has been thought previously to occur sporadically in most patients, there is increasing evidence of a genetic contribution to the disorder. Recently, a polymorphic variant within intron 6 of the Nurr1 gene was reported to be associated with sporadic and familial PD. In an effort to identify susceptibility genes for PD, we have collected 783 PD patients from 372 families and 397 healthy controls from 217 families. PD patients and healthy controls were genotyped for the intron 6 insertion polymorphism by BseRI restriction endonuclease digestion. No significant difference in either homozygosity or heterozygosity for the 7048G7049 (IVS6 1361 +16insG) polymorphism was detected in the PD patient cohort as compared with the panel of healthy controls. Moreover, direct sequencing of exon 1 of the Nurr1 gene in PD patients failed to detect either of the two recently reported Nurr1 mutations identified in a small subset of a PD patient cohort. Taken together, these data suggest that genetic alteration at the Nurr1 locus is not a significant risk factor for the development of Parkinson's disease in our large sample of familial PD patients. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197702     DOI: 10.1002/mds.20097

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.

Authors:  Chun-Hyung Kim; Baek-Soo Han; Jisook Moon; Deog-Joong Kim; Joon Shin; Sreekanth Rajan; Quoc Toan Nguyen; Mijin Sohn; Won-Gon Kim; Minjoon Han; Inhye Jeong; Kyoung-Shim Kim; Eun-Hye Lee; Yupeng Tu; Jacqueline L Naffin-Olivos; Chang-Hwan Park; Dagmar Ringe; Ho Sup Yoon; Gregory A Petsko; Kwang-Soo Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

2.  Copy number variation in familial Parkinson disease.

Authors:  Nathan Pankratz; Alexandra Dumitriu; Kurt N Hetrick; Mei Sun; Jeanne C Latourelle; Jemma B Wilk; Cheryl Halter; Kimberly F Doheny; James F Gusella; William C Nichols; Richard H Myers; Tatiana Foroud; Anita L DeStefano
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

3.  Nurr1 promotes neurogenesis of dopaminergic neuron and represses inflammatory factors in the transwell coculture system of neural stem cells and microglia.

Authors:  Xiao-Xiang Chen; Yuan Qian; Xiang-Peng Wang; Zhi-Wei Tang; Jiao-Tian Xu; Hai Lin; Zhi-Yong Yang; Xiao-Bin Song; Di Lu; Jia-Zhi Guo; Li-Gong Bian; Yu Li; Lei Zhou; Xing-Li Deng
Journal:  CNS Neurosci Ther       Date:  2018-02-15       Impact factor: 5.243

4.  Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.

Authors:  Howard J Federoff
Journal:  Neurotox Res       Date:  2009-04-24       Impact factor: 3.911

Review 5.  Genetics of parkinsonism.

Authors:  Alistair J Lewthwaite; David J Nicholl
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 6.  The regulation and deregulation of Wnt signaling by PARK genes in health and disease.

Authors:  Daniel C Berwick; Kirsten Harvey
Journal:  J Mol Cell Biol       Date:  2013-10-09       Impact factor: 6.216

7.  Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.

Authors:  Jun Wang; Weina Bi; Wei Zhao; Merina Varghese; Rick J Koch; Ruth H Walker; Roshantha A Chandraratna; Martin E Sanders; Amanda Janesick; Bruce Blumberg; Libby Ward; Lap Ho; Giulio M Pasinetti
Journal:  Oncotarget       Date:  2016-02-16

8.  Genomewide association study for onset age in Parkinson disease.

Authors:  Jeanne C Latourelle; Nathan Pankratz; Alexandra Dumitriu; Jemma B Wilk; Stefano Goldwurm; Gianni Pezzoli; Claudio B Mariani; Anita L DeStefano; Cheryl Halter; James F Gusella; William C Nichols; Richard H Myers; Tatiana Foroud
Journal:  BMC Med Genet       Date:  2009-09-22       Impact factor: 2.103

9.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease.

Authors:  Nathan Pankratz; Jemma B Wilk; Jeanne C Latourelle; Anita L DeStefano; Cheryl Halter; Elizabeth W Pugh; Kimberly F Doheny; James F Gusella; William C Nichols; Tatiana Foroud; Richard H Myers
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

Review 10.  Retrograde Axonal Degeneration in Parkinson Disease.

Authors:  Patricia Tagliaferro; Robert E Burke
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.